Myeloma bone disease: A constant problem in the changing landscape of myeloma management.
1/5 보강
Outcomes for patients with multiple myeloma have improved markedly in recent years due to the introduction of highly effective immune-mediated anti-myeloma therapies in both newly diagnosed and relaps
APA
Swan D, Yong A, et al. (2026). Myeloma bone disease: A constant problem in the changing landscape of myeloma management.. British journal of haematology, 208(2), 399-412. https://doi.org/10.1111/bjh.70240
MLA
Swan D, et al.. "Myeloma bone disease: A constant problem in the changing landscape of myeloma management.." British journal of haematology, vol. 208, no. 2, 2026, pp. 399-412.
PMID
41178408 ↗
Abstract 한글 요약
Outcomes for patients with multiple myeloma have improved markedly in recent years due to the introduction of highly effective immune-mediated anti-myeloma therapies in both newly diagnosed and relapsed patients. Conversely, while patients are living longer, myeloma bone disease continues to contribute significantly to morbidity and mortality. Routine incorporation of anti-resorptive therapies into patient management is recommended by consensus guidelines; however, patients continue to sustain skeletal-related events, including pathological fractures. In this review, we discuss the diagnosis and pathogenesis of myeloma bone disease and the evidence underpinning guideline recommendations for the use of bisphosphonates in patients with myeloma. We consider novel approaches to reducing bone disease presented by targeting osteoblastic activity, the impact of anti-myeloma therapies themselves on bone disease and the role of biomarkers to monitor disease activity and guide the intensity and duration of bone-targeted therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.